What do systematic reviews say?

Intervention not reported

The intervention may leads to higher diarrhoea ‐ Aliskiren 600 mg vs placebo (low certainty).

• Blood pressure lowering efficacy of renin inhibitors for primary hypertension 2017 · Cochrane Headline outcomes only
  RR 7 [2.48, 19.72]
  2 studies · 592 participants
  Low

Intervention not reported

The intervention showed no clear difference in death or major disability by 18 to 24 months corrected age (aligned… (high certainty).

• Effects of targeting lower versus higher arterial oxygen saturations on death or disability in preterm infants 2017 · Cochrane Headline outcomes only
  RR 1.04 [0.98, 1.1]
  5 studies · 4754 participants
  High

Intervention not reported

The intervention leads to higher death to 18 to 24 months corrected age (high certainty).

• Effects of targeting lower versus higher arterial oxygen saturations on death or disability in preterm infants 2017 · Cochrane Headline outcomes only
  RR 1.16 [1.03, 1.31]
  5 studies · 4873 participants
  High

Intervention not reported

The intervention showed no clear difference in major disability by 18 to 24 months corrected age (aligned definition) (high certainty).

• Effects of targeting lower versus higher arterial oxygen saturations on death or disability in preterm infants 2017 · Cochrane Headline outcomes only
  RR 1.01 [0.93, 1.09]
  5 studies · 3867 participants
  High

Intervention not reported

The intervention probably leads to lower retinopathy of prematurity requiring treatment (moderate certainty).

• Effects of targeting lower versus higher arterial oxygen saturations on death or disability in preterm infants 2017 · Cochrane Headline outcomes only
  RR 0.72 [0.61, 0.85]
  5 studies · 4089 participants
  Moderate

Intervention not reported

The intervention leads to higher necrotising enterocolitis (high certainty).

• Effects of targeting lower versus higher arterial oxygen saturations on death or disability in preterm infants 2017 · Cochrane Headline outcomes only
  RR 1.24 [1.05, 1.47]
  5 studies · 4929 participants
  High

Intervention not reported

The intervention showed no clear difference in blindness (moderate certainty).

• Effects of targeting lower versus higher arterial oxygen saturations on death or disability in preterm infants 2017 · Cochrane Headline outcomes only
  RR 1.13 [0.65, 1.97]
  5 studies · 3875 participants
  Moderate

Silodosin vs placebo

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 1743 participants
  Low

Silodosin vs tamsulosin

Silodosin probably leads to higher sexual adverse events compared with tamsulosin (moderate certainty).

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  RR 6.05 [3.55, 10.31]
  10 studies · 1849 participants
  Moderate

Silodosin vs naftopidil

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 652 participants
  Low

Silodosin vs naftopidil

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 652 participants
  Low

Silodosin vs naftopidil

Silodosin showed no clear difference in treatment withdrawal due to any reason compared with naftopidil (low certainty).

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  RR 1.25 [0.81, 1.93]
  4 studies · 659 participants
  Low

Silodosin vs naftopidil

Silodosin showed no clear difference in cardiovascular adverse events compared with naftopidil (low certainty).

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  RR 1.02 [0.41, 2.56]
  5 studies · 808 participants
  Low

Silodosin vs naftopidil

Silodosin probably leads to higher sexual adverse events compared with naftopidil (moderate certainty).

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  RR 5.93 [2.16, 16.29]
  4 studies · 405 participants
  Moderate

Silodosin vs alfuzosin

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 60 participants
  Low

Silodosin vs alfuzosin

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 60 participants
  Moderate

Silodosin vs alfuzosin

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 60 participants
  Low

Silodosin vs alfuzosin

Silodosin showed no clear difference in cardiovascular adverse events compared with alfuzosin (low certainty).

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  RR 0.67 [0.36, 1.24]
  1 study · 60 participants
  Low

Silodosin vs placebo

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 820 participants
  Moderate

Silodosin vs alfuzosin

Silodosin probably leads to higher sexual adverse events compared with alfuzosin (moderate certainty).

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  RR 37.21 [5.32, 260.07]
  1 study · 95 participants
  Moderate